J Korean Diabetes.  2023 Sep;24(3):148-153. 10.4093/jkd.2023.24.3.148.

Characteristics of the Latest Therapeutic Agent for Diabetes

• Yun N

• KMID: 2546632
• DOI: http://doi.org/10.4093/jkd.2023.24.3.148

Abstract

The latest therapeutic agent for diabetes is characterized by a longer lasting blood glucose control effect than existing treatments and stable blood glucose control. In addition, it has the advantage of being able to manage not only diabetes, but also comorbidities by considering the characteristics of each patient, such as comorbidities (atherosclerotic cardiovascular disease, chronic kidney disease, etc.). In this chapter, new antidiabetic drugs will be introduced based on the latest clinical research results on drugs such as sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

Keyword

Glucagon-like peptide-1 receptor; Hypoglycemic agents; Sodium-glucose transporter 2 inhibitors

Reference

1.Korean Diabetes Association. 2023 Clinical practice guidelines for diabetes. 8th ed.Seoul: Korean Diabetes Association;2023. Summary of 2023 clinical practice guidelines for diabetes. p. 4–7.

2.Korean Diabetes Association. 2023 Clinical practice guidelines for diabetes. 8th ed.Seoul: Korean Diabetes Association;2023. Chapter. 11. Drug treatment for type 2 diabetes. p. 123–76.

3.Kwak SH., Han KA., Kim KS., Yu JM., Kim E., Won JC, et al. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, placebo-con-trolled, phase III trial. Diabetes Obes Metab. 2023. 25:1865–73.

4.Bhatt DL., Szarek M., Pitt B., Cannon CP., Leiter LA., Mc-Guire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021. 384:129–39.

5.Filippatos G., Anker SD., Agarwal R., Ruilope LM., Rossing P., Bakris GL, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022. 145:437–47.

6.Rodbard HW., Rosenstock J., Canani LH., Deerochanawong C., Gumprecht J., Lindberg SØ, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes un-controlled on metformin: the PIONEER 2 trial. Diabetes Care. 2019. 42:2272–81.

7.Abdelmalek MF., Suzuki A., Sanchez W., Lawitz E., Filozof C., Cho H, et al. A phase 2, adaptive randomized, dou-ble-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alco-holic steatohepatitis - study design and rationale of HM-TRIA-201 study. Contemp Clin Trials. 2023. 130:107176.

8.Jastreboff AM., Aronne LJ., Ahmad NN., Wharton S., Con-nery L., Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. 387:205–16.

9.ClinicalTrials.gov. Phase 1 study to evaluate the safety and tolerability of VK2735. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05203237 (updated 2023 May 19).

10.Bajaj HS., Bergenstal RM., Christoffersen A., Davies MJ., Gowda A., Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021. 44:1586–94.

11.Ministry of Food and Drug Safety. Icosema clinical trial information. Available from: https://nedrug.mfds.go.kr/searchClinic?page=1&-searchYn=true&approv-alStart=2020-07-27&approvalEnd=2023-07-27&search-Type=ST2&searchKeyword=icosema&approvalDtStart=2020-07-27&approvalDtEnd=2023-07-27&clinicStep-Code=15&examFinish=&domestic=&gender=&age=&lo-calList=000&local-List2=000.

12.Kim Y., Lee SW., Wang H., Kim RH., Park HK., Lee H, et al. DA-1241, a novel GPR119 agonist, improves hypergly-caemia by inhibiting hepatic gluconeogenesis and enhancing insulin secretion in diabetic mice. Diabetes Metab J. 2022. 46:337–48.

13.ClinicalTrials.gov. IDG-16177 for the evaluation of its safety and pharmacokinetics. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04982705 (updated 2022 Aug 11).

14.Ministry of Food and Drug Safety. Prescribing information for Benavo. Available from: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202204353aupdateTs2023-07-03%2017:55:00.0b (updated 2023 Mar 3).

15.Han KA., Kim YH., Kim DM., Lee BW., Chon S., Sohn TS, et al. Efficacy and safety of enavogliflozin versus dapagli-flozin as add-on to metformin in patients with type 2 diabetes mellitus: a 24-week, double-blind, randomized trial. Diabetes Metab J. 2023. doi: 10.4093/dmj.2022.0315 [Epub ahead of print].

16.Kim KS., Han KA., Kim TN., Park CY., Park JH., Kim SY, et al. Efficacy and safety of enavogliflozin versus dapagli-flozin added to metformin plus gemigliptin treatment inpatients with type 2 diabetes: a double-blind, randomized, comparator-active study: ENHANCE-D study. Diabetes Metab. 2023. 49:101440.

17.Bhatt DL., Szarek M., Steg PG., Cannon CP., Leiter LA., Mc-Guire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021. 384:117–28.

18.U.S. Food and Drug Administration. Prescribing information for INPEFA. Available from: https://www.accessda-ta.fda.gov/drugsatfda_docs/label/2023/216203s000lbl.pdf (updated 2023 May).

19.Ministry of Food and Drug Safety. Prescribing information for Rybelsus. Available from: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202201785aupdateTs2023-07-03%2017:55:00.0b (updated 2023 Aug 22).

20.Rubino D., Abrahamsson N., Davies M., Hesse D., Greenway FL., Jensen C, et al. Effect of continued weekly sub-cutaneous semaglutide vs placebo on weight loss mainte-nance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. 325:1414–25.

21.Rosenstock J., Wysham C., Frías JP., Kaneko S., Lee CJ., Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021. 398:143–55.

22.Lingvay I., Cheng AY., Levine JA., Gomez-Valderas E., Allen SE., Ranta K, et al. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: a post hoc analysis of the SURPASS−1 to −5 studies. Diabetes Obes Metab. 2023. 25:965–74.